Samsung

Russian infliximab biosimilar has been proved equivalent to Remicade® in international clinical trials

New Delhi, February 21, 2018: In January 2018, BIOCAD’s infliximab biosimilar was approved in Russia. The approval was based on…

6 years ago

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home2/theprkho/public_html/thepharmatimes.in/wp-includes/functions.php on line 5420